GLP-1 Drugs Linked to Increased Osteoporosis Risk in New Research
Recent research has identified a potential link between GLP-1 weight loss medications and an increased risk of osteoporosis. These drugs, which are commonly used to manage obesity and Type 2 diabetes, may lead to a 30% higher risk of developing osteoporosis. The increased risk is believed to be associated with rapid weight loss and its effects on bone density. Angela Roy, a Physician's Assistant at Baton Rouge General's Bone Health Center, explains that while the drugs offer significant benefits, they may also contribute to bone health issues due to mechanical unloading from loss of body and muscle mass, coupled with nutritional deficiencies. Patients on these medications may not consume adequate protein, calcium, or vitamin D, which are essential for maintaining bone health. 
